Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Journal of Liver Cancer ; : 94-99, 2017.
Article in Korean | WPRIM | ID: wpr-156762

ABSTRACT

Liver cancer is more complex to treat compared to cancers in other organs, since liver function should be considered. In addition, only a few patients can be applied curative treatment due to advanced stage at diagnosis. Therefore, early stage detection is important and has been increased through screening and surveillance programs using image modalities recently. However, it is still difficult to diagnose small or hypovascular hepatocellular carcinoma (HCC) even using advanced image modalties. In particular, hypovascular HCCs do not show arterial contrast enhancement which is a typical finding of HCC on computed tomography (CT) and magnetic resonance imaging (MRI). Those also account for a considerable portion of early HCC. We present 54 yearsold man who had recurrent hypervascular and hypovascular nodules on three phase CT and gadoxetic acid-enhanced MRI. The nodules were removed by surgical resection and confirmed as combined hepatocellular-cholangiocarcinoma and well differentiated HCC respectively.


Subject(s)
Humans , Carcinoma, Hepatocellular , Cholangiocarcinoma , Diagnosis , Early Diagnosis , Liver , Liver Neoplasms , Magnetic Resonance Imaging , Mass Screening
2.
Clinical and Molecular Hepatology ; : 487-494, 2016.
Article in English | WPRIM | ID: wpr-54509

ABSTRACT

BACKGROUND/AIMS: Practice guidelines recommend endoscopic band ligation (EBL) and endoscopic variceal obturation (EVO) for bleeding from esophageal varices and fundal varices, respectively. However, the optimal treatment for bleeding from cardiac varices along the lesser curvature of the stomach (GOV1) remains undefined. This retrospective study compared the efficacy between EBL and EVO for bleeding from GOV1. METHODS: Patients treated by EBL or EVO via cyanoacrylate injection for bleeding from GOV1 were enrolled. Patients diagnosed with hepatocellular carcinoma or treated with endoscopic injection sclerotherapy were excluded. RESULTS: The study included 91 patients treated for bleeding from GOV1. The mean age was 56.3±10.9 years (mean±SD), and 78 of them (85.7%) were men. Overall, 51 and 40 patients were treated with EBL and EVO, respectively. A trend for a higher hemostasis rate was noted in the EVO group (100%) than in the EBL group (82.6%, P=0.078). Varices rebled in 15 patients during follow-up. The rebleeding rate was significantly higher in the EBL group than in the EVO group (P=0.004). During follow-up, 13 patients died (11 in the EBL group and 2 in the EVO group); the survival rate was marginally significant between two groups (P=0.050). The rebleeding-free survival rate was significantly higher in the EVO group than in the EBL group (P=0.001). CONCLUSIONS: Compared to EBL, EVO offered significantly lower rebleeding rates, significantly higher rebleeding-free survival rates, and a trend for higher hemostasis and survival rates. EVO appears to be the better therapeutic option for bleeding from GOV1.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Carcinoma, Hepatocellular/complications , Cyanoacrylates/therapeutic use , Disease-Free Survival , Endoscopy, Gastrointestinal , Gastrointestinal Hemorrhage/etiology , Ligation , Liver Cirrhosis/complications , Liver Neoplasms/complications , Proportional Hazards Models , Recurrence , Retrospective Studies , Sclerotherapy , Survival Rate , Treatment Outcome
3.
Clinical and Molecular Hepatology ; : 382-389, 2016.
Article in English | WPRIM | ID: wpr-188161

ABSTRACT

BACKGROUND/AIMS: Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. METHODS: This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log₁₀ IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal. RESULTS: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log₁₀ IU/mL (n=11) and >3 log₁₀ IU/mL (n=28), respectively. CONCLUSION: The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log₁₀ IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Alanine Transaminase/blood , Antiviral Agents/therapeutic use , DNA, Viral/blood , Follow-Up Studies , Guanine/analogs & derivatives , Hepatitis B Surface Antigens/blood , Hepatitis B virus/genetics , Hepatitis B, Chronic/drug therapy , Multivariate Analysis , Polymerase Chain Reaction , Recurrence , Treatment Outcome
4.
Clinical and Molecular Hepatology ; : 316-320, 2012.
Article in English | WPRIM | ID: wpr-52817

ABSTRACT

Transcatheter arterial chemoembolization (TACE) has been used widely to treat patients with unresectable hepatocellular carcinoma. However, this method can induce various adverse events caused by necrosis of the tumor itself or damage to nontumor tissues. In particular, neurologic side effects such as cerebral infarction and paraplegia, although rare, may cause severe sequelae and permanent disability. Detailed information regarding the treatment process and prognosis associated with this procedure is not yet available. We experienced a case of paraplegia that occurred after conducting TACE through the intercostal artery to treat hepatocellular carcinoma that had metastasized to the rib. In this case, TACE was attempted to relieve severe bone pain, which had persisted even after palliative radiotherapy. A sudden impairment of sensory and motor functions after TACE developed in the trunk below the level of the sternum and in both lower extremities. The patient subsequently received steroid pulse therapy along with supportive care and continuous rehabilitation. At the time of discharge the patient had recovered sufficiently to enable him to walk by himself, although some paresthesia and spasticity remained.


Subject(s)
Humans , Male , Middle Aged , Antiviral Agents/therapeutic use , Bone Neoplasms/diagnostic imaging , Carcinoma, Hepatocellular/diagnosis , Catheter Ablation , Chemoembolization, Therapeutic/adverse effects , Hepatitis B/complications , Liver Cirrhosis/etiology , Liver Neoplasms/diagnosis , Positron-Emission Tomography , Soft Tissue Neoplasms/secondary , Spinal Cord Injuries/etiology , Tomography, X-Ray Computed
5.
Clinical Endoscopy ; : 67-72, 2012.
Article in English | WPRIM | ID: wpr-213364

ABSTRACT

BACKGROUND/AIMS: Cryotherapy is the therapeutic application for tissue ablation. Clinical applications of cryotherpy such as in pulmonology have increased. Until now, its development in gastroenterology has been insignificant. But, as clinical application such as mucosal ablation on Barrett's esophagus became possible, various applications have been developed. Therefore, it is important to make standards of tissue injury's extent in cryotherapy prior to clinical trial. We evaluated the tissue injury according to the application of cryoprobe with a pig model. METHODS: Cryoprobe was applied to several different segments of the esophagus and stomach for various lengths of time using various number of probe's contact in a pig model. After 48 hours, esophagus and stomach were harvested and histological tissue injury was assessed. The extent of tissue injury was decided by the injury of the deepest layer. RESULTS: Endoscopic application of cryoprobe on esophagus and stomach resulted in a dose-dependent injury: esophageal necrosis was limited to the submucosa after 10 seconds of cryotherapy, and extended to involve the transmural necrosis after over 15 seconds. Necrosis on stomach was extended to involve the transmural necrosis after over 20 seconds. CONCLUSIONS: Positive relationship was seen between the duration and frequency of cryoprobe application and the extent of tissue injury.


Subject(s)
Barrett Esophagus , Cryotherapy , Esophagus , Gastroenterology , Necrosis , Pulmonary Medicine , Stomach
6.
Chonnam Medical Journal ; : 177-180, 2011.
Article in English | WPRIM | ID: wpr-788211

ABSTRACT

We report a case of thymic carcinoma that was initially detected by echocardiography in an 80-year-old male who visited the emergency room for chest pain and had a history of myocardial infarction and percutaneous coronary intervention. Transthoracic echocardiography showed a huge extracardiac mass that was located in the anterior mediastinum and was diagnosed as a thymic carcinoma by biopsy.


Subject(s)
Aged, 80 and over , Humans , Male , Biopsy , Chest Pain , Echocardiography , Emergencies , Heart , Mediastinum , Molecular Weight , Myocardial Infarction , Percutaneous Coronary Intervention , Thorax , Thymoma
7.
Intestinal Research ; : 238-242, 2011.
Article in Korean | WPRIM | ID: wpr-51732

ABSTRACT

Cronkhite-Canada syndrome (CCS) is a rare, non-familial hamartomatous polyposis syndrome characterized by multiple polyps in the entire gastrointestinal tract, nail dystrophy, skin pigmentation, and systemic alopecia. The clinical symptoms of this syndrome include diarrhea, abdominal pain, and alopecia often accompanied by taste disturbances, hypoalbuminemia, recurrent infections, nutritional absorption disturbances, heart failure, and gastrointestinal bleeding. We report a patient with CCS who was admitted complaining of hematochezia, melena, and a 1 month history of diarrhea, nail changes, taste disturbances, and alopecia. Upper endoscopy, colonoscopy, and capsule endoscopy were performed and showed numerous polyps in the stomach, small intestine, and large intestine. Histological sections of these polyps showed edematous stroma and cystically dilated foveolar epithelium, which was consistent with CCS. We diagnosed CCS based on the clinical symptoms and the histological findings of the polyps found via endoscopy. We report on this case and review this syndrome.


Subject(s)
Humans , Abdominal Pain , Absorption , Alopecia , Capsule Endoscopy , Colonoscopy , Diarrhea , Endoscopy , Epithelium , Gastrointestinal Hemorrhage , Gastrointestinal Tract , Heart Failure , Hemorrhage , Hypoalbuminemia , Intestinal Polyposis , Intestine, Large , Intestine, Small , Melena , Nails , Polyps , Skin Pigmentation , Stomach
8.
Clinical Endoscopy ; : 137-139, 2011.
Article in English | WPRIM | ID: wpr-82697

ABSTRACT

Pseudomembranous colitis (PMC) is known to be associated with antibiotic treatment, but is not commonly related to antitubercular (anti-TB) agent, rifampin. PMC is frequently localized to rectum and sigmoid colon, which can be diagnosed with sigmoidoscopy. We report a case of rifampin-induced PMC with rectosigmoid sparing in a pulmonary tuberculosis patient. An 81-year-old man using anti-TB agents was admitted with a 30-day history of severe diarrhea and general weakness. On colonoscopy, nonspecific findings such as mucosal edema and erosion were found in sigmoid colon, whereas multiple yellowish plaques were confined to cecal mucosa only. Biopsy specimen of the cecum was compatible with PMC. Metronidazole was started orally, and the anti-TB medications excluding rifampin were readministerred. His symptoms remarkably improved within a few days without recurrence. Awareness of rectosigmoid sparing PMC in patients who develop diarrhea during anti-TB treatment should encourage early total colonoscopy.


Subject(s)
Aged, 80 and over , Humans , Biopsy , Cecum , Colon, Sigmoid , Colonoscopy , Diarrhea , Edema , Enterocolitis, Pseudomembranous , Metronidazole , Mucous Membrane , Rectum , Recurrence , Rifampin , Sigmoidoscopy , Tuberculosis, Pulmonary
9.
Chonnam Medical Journal ; : 177-180, 2011.
Article in English | WPRIM | ID: wpr-82688

ABSTRACT

We report a case of thymic carcinoma that was initially detected by echocardiography in an 80-year-old male who visited the emergency room for chest pain and had a history of myocardial infarction and percutaneous coronary intervention. Transthoracic echocardiography showed a huge extracardiac mass that was located in the anterior mediastinum and was diagnosed as a thymic carcinoma by biopsy.


Subject(s)
Aged, 80 and over , Humans , Male , Biopsy , Chest Pain , Echocardiography , Emergencies , Heart , Mediastinum , Molecular Weight , Myocardial Infarction , Percutaneous Coronary Intervention , Thorax , Thymoma
SELECTION OF CITATIONS
SEARCH DETAIL